Recursion Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75629V1044
SecurityMX:RXRX / Recursion Pharmaceuticals, Inc.
InstitutionUBS Group AG
Latest Disclosed Ownership5,101,237 shares
Latest Disclosed Value $ 15,660,798
UBS Group AG ownership in RXRX / Recursion Pharmaceuticals, Inc.

On May 5, 2026 - UBS Group AG filed a 13F-HR form disclosing ownership of 5,101,237 shares of Recursion Pharmaceuticals, Inc. (MX:RXRX) valued at $15,660,798 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 29, 2026 disclosing 3,692,022 shares of Recursion Pharmaceuticals, Inc.. This represents a change in shares of 38.17% during the quarter.

UBS Group AG has a history of taking positions in derivatives of the underlying security (RXRX) in the form of stock options. The firm currently holds call options representing 43,152 of underlying shares valued at $132,477 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

MX:RXRX / Recursion Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-05 2026-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 5,101,237 1,409,215 38.17 15,661 3.71 0.0004
2026-01-29 2025-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 3,692,022 -61,756 -1.65 15,100 -17.57 0.0004
2025-11-13 2025-09-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 3,753,778 -876,812 -18.94 18,318 -21.82 0.0029
2025-08-14 2025-06-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 4,630,590 -939,192 -16.86 23,431 -20.48 0.0041
2025-05-13 2025-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 5,569,782 2,565,137 85.37 29,464 45.06 0.0054
2025-02-14 2024-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 3,004,645 2,204,785 275.65 20,311 285.33 0.0038
2024-11-14 2024-09-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 799,860 -849,190 -51.50 5,271 -57.38 0.0011
2024-08-14 2024-06-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 1,649,050 976,619 145.24 12,368 84.47 0.0031
2024-05-13 2024-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 672,431 -19,480 -2.82 6,704 -1.73 0.0017
2024-02-09 2023-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 691,911 349,232 101.91 6,822 160.28 0.0020
2023-11-09 2023-09-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 342,679 173,954 103.10 2,621 108.02 0.0009
2023-08-11 2023-06-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 168,725 -210 -0.12 1,260 11.90 0.0004
2023-05-12 2023-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 168,935 -192,960 -53.32 1,127 -59.64 0.0004
2023-02-08 2022-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 361,895 343,430 1,859.90 2,790 1,323.47 0.0010
2022-11-10 2022-09-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 18,465 13,479 270.34 196 378.05 0.0001
2022-08-10 2022-06-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 4,986 -1,941 -28.02 41 -16.33 0.0000
2022-05-16 2022-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 6,927 -252,295 -97.33 49 -98.90 0.0000
2022-02-14 2021-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 259,222 188,079 264.37 4,440 171.23 0.0013
2021-11-15 2021-09-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 71,143 70,443 10,063.29 1,637 6,196.15 0.0005
2021-08-13 2021-06-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 700 700 26 0.0000
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-05 2026-03-31 13F RECURSION PHARMACEUTICALS IN CL A Call 43,152 0.00 132 -25.00 n/a n/a n/a
2026-01-29 2025-12-31 13F RECURSION PHARMACEUTICALS IN CL A Call 43,152 -77.06 176 -80.81 n/a n/a n/a
2025-11-13 2025-09-30 13F RECURSION PHARMACEUTICALS IN CL A Call 188,100 918 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.